PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 135 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,185 | -39.6% | 131 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $3,618 | +20.1% | 131 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,013 | -20.0% | 131 | -62.0% | 0.00% | 0.0% |
| Q4 2022 | $3,764 | +25.5% | 345 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 345 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | -66.7% | 345 | +38.0% | 0.00% | -60.0% |
| Q4 2021 | $9,000 | +125.0% | 250 | 0.0% | 0.01% | +150.0% |
| Q3 2021 | $4,000 | -63.6% | 250 | 0.0% | 0.00% | -66.7% |
| Q2 2021 | $11,000 | +83.3% | 250 | 0.0% | 0.01% | +100.0% |
| Q1 2021 | $6,000 | +200.0% | 250 | +110.1% | 0.00% | +200.0% |
| Q4 2020 | $2,000 | 0.0% | 119 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $2,000 | +100.0% | 119 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,000 | -66.7% | 119 | -52.8% | 0.00% | 0.0% |
| Q3 2018 | $3,000 | – | 252 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |